Amylyx Pharmaceuticals Inc (AMLX)
2.03
+0.03
(+1.50%)
USD |
NASDAQ |
May 03, 16:00
2.035
0.00 (0.00%)
After-Hours: 20:00
Amylyx Pharmaceuticals Cash from Investing (TTM): 92.05M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 92.05M |
September 30, 2023 | -157.05M |
June 30, 2023 | 35.08M |
March 31, 2023 | -83.68M |
December 31, 2022 | -238.99M |
Date | Value |
---|---|
September 30, 2022 | -7.994M |
June 30, 2022 | -141.24M |
March 31, 2022 | -145.70M |
December 31, 2021 | -46.41M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-238.99M
Minimum
Dec 2022
92.05M
Maximum
Dec 2023
-77.10M
Average
-83.68M
Median
Mar 2023
Cash from Investing (TTM) Benchmarks
Cassava Sciences Inc | -0.414M |
iRhythm Technologies Inc | -1.209M |
Bristol-Myers Squibb Co | -21.70B |
Moderna Inc | 2.313B |
ACADIA Pharmaceuticals Inc | 32.00M |